HyTest Ltd  

Cardiac troponin I is currently considered to be the gold standard biomarker test for myocardial infarction. Moreover, cTnI measurements by a new generation of high sensitivity cTnI assays could be helpful for long-term risk stratification of different patient groups, including patients with heart failure or stable coronary artery disease.

At HyTest, we have intensively studied troponin I for over 20 years. Based on this research, we constantly aim to develop improved antibodies from different sources, both hydridoma and recombinant, to be used in the immunoassays that are needed for accurate cardiac disease diagnostics. We have generated and tested recombinant troponins, and troponin secondary and ternary complexes, as well as several monoclonal antibodies and specific to different regions of the cTnI molecule and have tested numerous different MAb combinations to find the best pairs for a precise and sensitive cTnI immunoassay for several platforms.

D-dimer (MW 180 kDa) is the final product of fibrin degradation, which are produced during fibrinolysis in which the fibrin clots are digested by plasmin, and fibrin degradation products (FDP) of different molecular weights. Elevated levels of D-dimer have been found in the blood of patients with pulmonary embolism (PE) and deep vein thrombosis (DVT). The elevated level of D-dimer in blood is believed to be a reliable marker of pathological coagulation. During the COVID-19 pandemic D-dimer has been commonly elevated in patients with SARS-CoV-2. It has been shown to correlate with disease severity and to be a reliable prognostic marker for hospitalization and mortality assessment in patients admitted for COVID-19.

HyTest offers a suite of SARS-CoV-2 reagents for immunoassay development. Antibodies have been carefully characterized and tested with clinical samples. Also, we constantly monitor the emergence of new virus variants and when needed and possible, study if the mutations affect the binding properties of the antibodies. Our polyclonal antibodies can be used in combination with monoclonals; they do not recognize seasonal coronaviruses, however, they offer a broader range of specificity to SARS-CoV-2 variants. Set of recombinant antibodies can be used e.g. as positive controls.  

We also offer reagents for the development of antibody neutralising assays: recombinant RBD and ACE2 as well as an anti-RBD antibody with strong neutralising properties suitable to be used as a calibrator in the assay.